Latest Conference Articles

Functional air trapping in emphysematous lung regions may predict pneumothorax after BLVR, per ATS 2026 data presented by Isam Albaba, MBBS, from Temple University.

Amit Gupta, MBBS, DNB, joins the show to discuss diabetes treatment in a traditionally underserved population and to address the IDF’s work in moving it forward.

Payel Gupta, MD, discusses how IgE, FeNO, and type 2 comorbidities inform biologic choice and when a lack of response warrants switching agents.

Sparrow Pharmaceuticals presented phase 2a data for the HSD-1 inhibitor clofutriben at ADA 2026.

Phase 2 findings presented at ATS 2026 by Gerald Criner, MD, show pegtarazimod cut supplemental oxygen needs in hospitalized AE-COPD patients for up to 60 days.

At ATS 2026, Robert Wallis, MD, discussed PanTB-HM findings on FEV1 recovery and NAC antimicrobial interactions.

Ketan Dhatariya, MD, PhD, MS, joins the show to discuss how therapies for diabetes have evolved in the UK in comparison to the US.

Phase 4 PASSAGE data from ATS 2026 show tezepelumab reduced exacerbation rates across a diverse real-world cohort, including smokers, adolescents, and patients with comorbid COPD.

twiist improved time in range by 16 percentage points and reduced HbA1c by 0.7 points over 13 weeks in insulin-treated adults with type 2 diabetes, with no severe hypoglycemia events.

Trang Ly, PhD, MBBS, joins the show to discuss Insulet’s recent advancements in automated insulin delivery and the trajectory of the Omnipod platform.

DKA remains a growing challenge in diabetes care, with new data highlighting missed diagnoses, rising admissions, and higher costs.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Across a trio of phase 3 trials, CagriSema delivered superior HbA1c reduction and weight loss versus semaglutide in adults with type 2 diabetes

Vivian Fonseca, MD, explains data showing nearly half of patients with T2D discontinued GLP-1 therapy within 1 year, reducing their likelihood of achieving weight loss and HbA1c goals.

Timothy Garvey, MD, discusses petrelintide’s efficacy in patients with overweight and obesity, as well as its comparably low incidence of gastrointestinal effects.

Orforglipron added to titrated insulin glargine reduced HbA1c by up to 2.05% and body weight by up to 6.1% versus placebo, without increasing hypoglycemia risk.

Carel le Roux, PhD, discusses the full results from SYNCHRONIZE-1, a trial investigating Boehringer Ingelheim’s dual GLP-1/glucagon agonist.

In a post-hoc analysis of ATTAIN-1 and ATTAIN-2, the highest dose of orforglipron delivered meaningful weight loss across all menopause stages.

Shah explains proactive ketone monitoring, home DKA prevention strategies, and the future of continuous ketone monitoring.

Viral Shah, MD, outlines the case for earlier ketone detection across diabetes types, the limitations of urine testing, and what CKM technology may change in clinical practice.

Eugene Wright, Jr., MD, joins the show to discuss the current state of technological integration into diabetes care, from glucose monitors to insulin delivery and beyond.

Buse discusses phase VESPER results, berobenatide's weight loss potential, and expectations for the upcoming phase 3 program

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.

The CONNECT trial found CGM improved A1C and time in range in adults with type 2 diabetes not on insulin.

VESPER-1 and VESPER-3 findings highlight the potential of berobenatide, an investigational ultra-long-acting GLP-1 RA, for overweight or obesity with or without type 2 diabetes.

STEP UP T2D data suggest semaglutide 7.2 mg's superiority to the 2.4 mg dose and placebo for proposed BMI and waist-to-height ratio treatment targets.

An EHR-based machine learning model predicted 10-year type 2 diabetes risk with near-ideal calibration in over 3 million adult patients.